Evidence map›Paper›PMID 40679547›Full record

ReviewCurrent atherosclerosis reports2025

ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?

Marta Biolo, Federica Galimberti, Camilla Portinari, Sandra Bertocco, Paola Tosin, Manuela Casula, Lorenzo Previato, Sabina Zambon, Paolo Simioni, Alberto Zambon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Dysfunctional high-density lipoprotein: an updated review.Frontiers in cardiovascular medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marta BioloDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Federica GalimbertiIRCCS MultiMedica, Sesto San Giovanni (Milan), Milan, Italy.
Camilla PortinariDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Sandra BertoccoDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Paola TosinDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Manuela CasulaIRCCS MultiMedica, Sesto San Giovanni (Milan), Milan, Italy.
Lorenzo PreviatoDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Sabina ZambonDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Paolo SimioniDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Alberto ZambonDepartment of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy. alberto.zambon@unipd.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewApolipoprotein C-III (ApoC-III) plays a pivotal role in triglyceride (TG) metabolism by inhibiting lipoprotein lipase and hepatic clearance of TG-rich lipoproteins, contributing to hypertriglyceridaemia and elevated cardiovascular risk, as well as a high risk of acute pancreatitis. This review aims to summarize current evidence on ApoC-III inhibition strategies. RECENT

findingsCurrent treatments targeting Apo C-III include two antisense oligonucleotides (ASOs) (volanesorsen and olezarsen), and a small interfering RNA (siRNA) (plozasiran). Volanesorsen, a second-generation ASO, has shown effectiveness in reducing TG and preventing acute pancreatitis, especially in patients with familial chylomicronemia syndrome (FCS). However, its use is limited by the risk of thrombocytopenia, likely related to its chemical structure rather than ApoC-III inhibition itself. Olezarsen, a third-generation ASO with GalNAc conjugation for targeted liver delivery, offers an improved safety profile and strong efficacy in lowering TG and atherogenic lipoproteins levels, making it a promising candidate for a broader clinical use. Plozasiran, a GalNAc-conjugated siRNA, has shown robust and sustained TG reductions with a favorable safety profile, and early data suggest it may also reduce acute pancreatitis risk. ApoC-III inhibition represents an innovative and effective approach in managing hypertriglyceridaemia and its complications. Further outcome-driven trials are essential to define its role in cardiovascular risk reduction.

Indexed as

Apolipoprotein C-IIIHypertriglyceridemiaOligonucleotides, AntisenseHumansOligonucleotidesPancreatitisRNA, Small InterferingApolipoprotein C-IIIISIS 304801OligonucleotidesOligonucleotides, AntisenseRNA, Small InterferingAntisense oligonucleotides (ASO)Apolipoprotein C-III (ApoC-III)Cardiovascular risk reductionHypertriglyceridaemiaSmall interfering RNA (siRNA)

Identifiers

PMID40679547

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.